title: [Rhabdomyolysis and unexplained malaise. Role of combination of ciprofibrate and norfloxacin].
authors.forename: H
authors.initials: H
authors.lastname: Blain
authors.forename: M
authors.initials: M
authors.lastname: Klein
authors.forename: G
authors.initials: G
authors.lastname: Weryha
authors.forename: P
authors.initials: P
authors.lastname: Tréchot
authors.forename: B
authors.initials: B
authors.lastname: Hanesse
authors.forename: J
authors.initials: J
authors.lastname: Leclère
mesh_terms: D000890:Anti-Infective Agents / Q000009:adverse effects*; D002995:Clofibric Acid / Q000009:adverse effects / Q000031:analogs & derivatives*; D004359:Drug Therapy, Combination; D005260:Female; D058607:Fibric Acids; D006801:Humans; D000960:Hypolipidemic Agents / Q000009:adverse effects*; D008875:Middle Aged; D009643:Norfloxacin / Q000009:adverse effects*; D012206:Rhabdomyolysis / Q000139:chemically induced*; D013575:Syncope / Q000139:chemically induced*
chemical_list: D000890:Anti-Infective Agents; D058607:Fibric Acids; D000960:Hypolipidemic Agents; D002995:Clofibric Acid; C019304:ciprofibrate; D009643:Norfloxacin
vernacular_title: Rhabdomyolyse et malaises inexpliqués. Rôle de l'association ciprofibrate et norfloxacine.